Mitotic kinesin inhibitors and methods of use thereof
This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.
1. A method of treating a disease in a human or animal that can be treated by inhibiting mitosis, wherein said disease is selected from the group consisting of acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma and myelodysplastic syndrome, comprising administering to said human or animal an effective amount of a compound of the Formula:
wherein:
X is S,
R is Z—NR 2 R 3 , Z—OH, or Z—OP(═O)(OR a )(OR a );
R 1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, saturated or partially unsaturated cycloalkyl, —OR 3 , —NR 4 OR 5 , CR b (═NOR c ), C(═O)R a , or —NR 4 R 5 , wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, and cycloalkyl are optionally substituted with one or more groups independently selected from oxo (with the proviso that it is not substituted on said aryl or heteroaryl), halogen, cyano, nitro, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, —O(C═O)OR d , —NR b SO 2 R d , —SO 2 NR a R b , —C(═O)R a , —C(═O)OR a , —OC(═O)R a , —OCH 2 C(═O)OR a , —NR b C(═O)OR d , —NR b C(═O)R a , —C(═O)NR a R b , —NR a R b , —NR c C(═O)NR a R b , —NR c C(NCN)NR a R b , —OR a , —OP(═O)(OR a ) 2 , alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl;
Ar 1 and Ar 2 are phenyl, wherein said phenyl is optionally substituted with one or more groups independently selected from F, Cl, Br, I, cyano, nitro, alkyl, alkenyl, alkynyl, saturated or partially unsaturated cycloalkyl, saturated or partially unsaturated heteorcycloalkyl, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, —OR a , —O(C═O)OR d , —OP(═O)(OR a )(OR a ), —NR a R b , —NR b SO 2 R d , —SO 2 NR a R b , —SR 6 , —SOR 6 , —SO 2 R 6 , —C(═O)R a , —C(═O)OR a , —OC(═O)R a , —OCH 2 C(═O)OR a , —NR b C(═O)OR d , —NR b C(═O)R a , —C(═O)NR a R b and —NR c C(═O)NR a R b ;
R 2 is hydrogen, —C(═O)R 4 , —SO 2 R 6 , alkyl, alkenyl, alkynyl, saturated or partially unsaturated cycloalkyl, wherein said alkyl, alkenyl, alkynyl, and cycloalkyl are optionally substituted with one or more groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, —O(C═O)OR d , —NR b SO 2 R d , —SO 2 NR a R b , —C(═O)R a , —C(═O)OR a , —OC(═O)R a , —NR b C(═O)OR d , —NR b C(═O)R a , —C(═O)NR a R b , —NR a R b , —NR c C(═O)NR a R b , —OR a , alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocycloalkyl and heterocyclylalkyl;
R 3 is hydrogen, —C(═O)R 4 , alkyl, alkenyl, alkynyl, or saturated or partially unsaturated cycloalkyl, wherein said alkyl, alkenyl, alkynyl, and cycloalkyl are optionally substituted with one or more groups independently selected from oxo (with the proviso that it is not substituted on said aryl or heteroaryl), halogen, cyano, nitro, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, —O(C═O)OR d , —OP(═O)(OR a ) 2 , —NR b SO 2 R d , —SO 2 NR a R b , —C(═O)R a , —C(═O)OR a , —OC(═O)R a , —NR b C(═O)OR d , —NR b C(═O)R a , —C(═O)NR a R b , —NR a R b , —NR c C(═O)NR a R b , —OR a , alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocycloalkyl and heterocyclylalkyl,
R 4 and R 5 are independently H, trifluoromethyl, difluoromethyl, fluoromethyl, alkyl, alkenyl, alkynyl, saturated or partially unsaturated cycloalkyl, aryl or heteroaryl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heteroaryl are optionally substituted with one or more groups independently selected from oxo (with the proviso that it is not substituted on said aryl or heteroaryl), halogen, cyano, nitro, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, —O(C═O)OR d , —NR b SO 2 R d , —SO 2 NR a R b , —C(═O)R a , —C(═O)OR a , —OC(═O)R a , —NR b C(═O)OR d , —NR b C(═O)R a , —C(═O)NR a R b , —NR a R b , —NR c C(═O)NR a R b , —NR c C(NCN)NR a R b , —OR a , alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl,
R 6 is alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or partially unsaturated cycloalkyl, saturated or partially unsaturated heterocycloalkyl, aryl or heteroaryl, wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more groups independently selected from oxo (with the proviso that it is not substituted on said aryl or heteroaryl), halogen, cyano, nitro, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, —O(C═O)OR d , —NR b SO 2 R d , —SO 2 NR a R b , —C(═O)R a , —C(═O)OR a , —OC(═O)R a , —NR b C(═O)OR d , —NR b C(═O)R a , —C(═O)NR a R b , —NR a R b , —NR c C(═O)NR a R b , —NR c C(NCN)NR a R b , —OR a , alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocycloalkyl and heterocyclylalkyl;
R a is hydrogen, trifluoromethyl, alkyl, alkenyl, alkynyl, saturated or partially unsaturated cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or saturated or partially unsaturated heterocyclylalkyl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl and heterocyclylalkyl are optionally substituted with one or more groups independently selected from oxo (with the proviso that it is not substituted on said aryl or heteroaryl), halogen, cyano, nitro, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, —O(C═O)OR h , —NR f SO 2 R h , —SO 2 NR e R f , —C(═O)R e , —C(═O)OR e , —OC(═O)R e , —NR f C(═O)OR h , —NR f C(═O)R e , —C(═O)NR e R f , —NR e R f , —NR g C(═O)NR e R f , —NR c C(NCN)NR e R f , —OR e , alkyl, alkenyl, alkynyl, saturated or partially unsaturated cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, saturated or partially unsaturated heterocycloalkyl and heterocyclylalkyl;
R b , R c , R f and R g are independently hydrogen or alkyl,
or R a and R b together with the atom to which they are attached form a 4 to 10 membered saturated or partially unsaturated heterocyclic ring which may include 1 to 3 additional heteroatoms, in addition to the nitrogen atom to which said R a and R b are attached, selected from N, O and S;
R d and R h are independently trifluoromethyl, alkyl, saturated or partially unsaturated cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, saturated or partially unsaturated heterocycloalkyl or heterocyclylalkyl;
R e is hydrogen, trifluoromethyl, alkyl, alkenyl, alkynyl, saturated or partially unsaturated cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, saturated or partially unsaturated heterocycloalkyl or heterocyclylalkyl; and
Z is alkylene having from 1 to 6 carbons, or alkenylene or alkynylene each having from 2 to 6 carbons, wherein said alkylene, alkenylene and alkynylene are optionally substituted with one or more groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, —O(C═O)OR d , —NR b SO 2 R d , —SO 2 NR a R b , —C(═O)R a , —C(═O)OR a , —OC(═O)R a , —NR b C(═O)OR d , —NR b C(═O)R a , —C(═O)NR a R b , —NR a R b , —NR c C(═O)NR a R b , —OR a , alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl,
or a pharmaceutical composition comprising said compound.
2. The method of claim 1 , wherein said compound is selected from:
or a pharmaceutically acceptable salt thereof.
3. The method of claim 2 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
4. The method of claim 2 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
5. The method of claim 2 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
6. The method of claim 2 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
7. The method of claim 2 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
8. The method of claim 2 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
9. The method of claim 6 , wherein the compound is administered in combination with a proteasome inhibitor.
10. The method of claim 9 , wherein the proteasome inhibitor is bortezomib.
11. The method of claim 9 , wherein the disease is selected from acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia and multiple myeloma.
12. The method of claim 11 , wherein the disease is selected from acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma.
13. The method of claim 12 , wherein the disease is acute myeloid leukemia.
14. The method of claim 12 , wherein the disease is chronic myeloid leukemia.
15. The method of claim 12 , wherein the disease is multiple myeloma.
16. The method of claim 10 , wherein the disease is selected from acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma.
17. The method of claim 16 , wherein the disease is acute myeloid leukemia.
18. The method of claim 16 , wherein the disease is chronic myeloid leukemia.
19. The method of claim 16 , wherein the disease is multiple myeloma.
20. The method of claim 7 , wherein the compound is administered in combination with a proteasome inhibitor.
21. The method of claim 20 , wherein the proteasome inhibitor is bortezomib.
22. The method of claim 20 , wherein the disease is selected from acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia and multiple myeloma.
23. The method of claim 22 , wherein the disease is selected from acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma.
24. The method of claim 23 , wherein the disease is acute myeloid leukemia.
25. The method of claim 23 , wherein the disease is chronic myeloid leukemia.
26. The method of claim 23 , wherein the disease is multiple myeloma.
27. The method of claim 21 , wherein the disease is selected from acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma.
28. The method of claim 27 , wherein the disease is acute myeloid leukemia.
29. The method of claim 27 , wherein the disease is chronic myeloid leukemia.
30. The method of claim 27 , wherein the disease is multiple myeloma.
31. A method of treating a hyperproliferative disorder, wherein said disorder is selected from the group consisting of acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative diseases, multiple myeloma and myelodysplastic syndrome, in a mammal that comprises administering to said mammal a therapeutically effective amount of a compound of the Formula:
wherein:
X is S,
R is Z—NR 2 R 3 , Z—OH, or Z—OP(═O)(OR a )(OR a );
R 1 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, saturated or partially unsaturated cycloalkyl, —OR 3 , —NR 4 OR 5 , CR b (═NOR c ), C(═O)R a , or —NR 4 R 5 , wherein said alkyl, alkenyl, alkynyl, aryl, heteroaryl, and cycloalkyl are optionally substituted with one or more groups independently selected from oxo (with the proviso that it is not substituted on said aryl or heteroaryl), halogen, cyano, nitro, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, —O(C═O)OR d , —NR b SO 2 R d , —SO 2 NR a R b , —C(═O)R a , —C(═O)OR a , —OC(═O)R a , —OCH 2 C(═O)OR a , —NR b C(═O)OR d , —NR b C(═O)R a , —C(═O)NR a R b , —NR a R b , —NR c C(═O)NR a R b , —NR c C(NCN)NR a R b , —OR a , —OP(═O)(OR a ) 2 , alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl;
Ar 1 and Ar 2 are phenyl, wherein said phenyl is optionally substituted with one or more groups independently selected from F, Cl, Br, I, cyano, nitro, alkyl, alkenyl, alkynyl, saturated or partially unsaturated cycloalkyl, saturated or partially unsaturated heteorcycloalkyl, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, —OR a , —O(C═O)OR d , —OP(═O)(OR a )(OR a ), —NR a R b , —NR b SO 2 R d , —SO 2 NR a R b , —SR 6 , —SOR 6 , —SO 2 R 6 , —C(═O)R a , —C(═O)OR a , —OC(═O)R a , —OCH 2 C(═O)OR a , —NR b C(═O)OR d , —NR b C(═O)R a , —C(═O)NR a R b and —NR c C(═O)NR a R b ;
R 2 is hydrogen, —C(═O)R 4 , —SO 2 R 6 , alkyl, alkenyl, alkynyl, saturated or partially unsaturated cycloalkyl, wherein said alkyl, alkenyl, alkynyl, and cycloalkyl are optionally substituted with one or more groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, —O(C═O)OR d , —NR b SO 2 R d , —SO 2 NR a R b , —C(═O)R a , —C(═O)OR a , —OC(═O)R a , —NR b C(═O)OR d , —NR b C(═O)R a , —C(═O)NR a R b , —NR a R b , —NR c C(═O)NR a R b , —OR a , alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocycloalkyl and heterocyclylalkyl;
R 3 is hydrogen, —C(═O)R 4 , alkyl, alkenyl, alkynyl, or saturated or partially unsaturated cycloalkyl, wherein said alkyl, alkenyl, alkynyl, and cycloalkyl are optionally substituted with one or more groups independently selected from oxo (with the proviso that it is not substituted on said aryl or heteroaryl), halogen, cyano, nitro, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, —O(C═O)OR d , —OP(═O)(OR a ) 2 , —NR b SO 2 R d , —SO 2 NR a R b , —C(═O)R a , —C(═O)OR a , —OC(═O)R a , —NR b C(═O)OR d , —NR b C(═O)R a , —C(═O)NR a R b , —NR a R b , —NR c C(═O)NR a R b , —OR a , alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocycloalkyl and heterocyclylalkyl,
R 4 and R 5 are independently H, trifluoromethyl, difluoromethyl, fluoromethyl, alkyl, alkenyl, alkynyl, saturated or partially unsaturated cycloalkyl, aryl or heteroaryl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, aryl and heteroaryl are optionally substituted with one or more groups independently selected from oxo (with the proviso that it is not substituted on said aryl or heteroaryl), halogen, cyano, nitro, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, —O(C═O)OR d , —NR b SO 2 R d , —SO 2 NR a R b , —C(═O)R a , —C(═O)OR a , —OC(═O)R a , —NR b C(═O)OR d , —NR b C(═O)R a , —C(═O)NR a R b , —NR a R b , —NR c C(═O)NR a R b , —NR c C(NCN)NR a R b , —OR a , alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl,
R 6 is alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, saturated or partially unsaturated cycloalkyl, saturated or partially unsaturated heterocycloalkyl, aryl or heteroaryl, wherein said alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with one or more groups independently selected from oxo (with the proviso that it is not substituted on said aryl or heteroaryl), halogen, cyano, nitro, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, —O(C═O)OR d , —NR b SO 2 R d , —SO 2 NR a R b , —C(═O)R a , —C(═O)OR a , —OC(═O)R a , —NR b C(═O)OR d , —NR b C(═O)R a , —C(═O)NR a R b , —NR a R b , —NR c C(═O)NR a R b , —NR c C(NCN)NR a R b , —OR a , alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocycloalkyl and heterocyclylalkyl;
R a is hydrogen, trifluoromethyl, alkyl, alkenyl, alkynyl, saturated or partially unsaturated cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or saturated or partially unsaturated heterocyclylalkyl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl and heterocyclylalkyl are optionally substituted with one or more groups independently selected from oxo (with the proviso that it is not substituted on said aryl or heteroaryl), halogen, cyano, nitro, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, —O(C═O)OR h , —NR f SO 2 R h , —SO 2 NR e R f , —C(═O)R e , —C(═O)OR e , —OC(═O)R e , —NR f C(═O)OR h , —NR f C(═O)R e , —C(═O)NR e R f , —NR e R f , —NR g C(═O)NR e R f , —NR c C(NCN)NR e R f , —OR e , alkyl, alkenyl, alkynyl, saturated or partially unsaturated cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, saturated or partially unsaturated heterocycloalkyl and heterocyclylalkyl;
R b , R c , R f and R g are independently hydrogen or alkyl,
or R a and R b together with the atom to which they are attached form a 4 to 10 membered saturated or partially unsaturated heterocyclic ring which may include 1 to 3 additional heteroatoms, in addition to the nitrogen atom to which said R a and R b are attached, selected from N, O and S;
R d and R h are independently trifluoromethyl, alkyl, saturated or partially unsaturated cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, saturated or partially unsaturated heterocycloalkyl or heterocyclylalkyl;
R e is hydrogen, trifluoromethyl, alkyl, alkenyl, alkynyl, saturated or partially unsaturated cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, saturated or partially unsaturated heterocycloalkyl or heterocyclylalkyl; and
Z is alkylene having from 1 to 6 carbons, or alkenylene or alkynylene each having from 2 to 6 carbons, wherein said alkylene, alkenylene and alkynylene are optionally substituted with one or more groups independently selected from oxo, halogen, cyano, nitro, trifluoromethyl, difluoromethyl, fluoromethyl, fluoromethoxy, difluoromethoxy, trifluoromethoxy, azido, —O(C═O)OR d , —NR b SO 2 R d , —SO 2 NR a R b , —C(═O)R a , —C(═O)OR a , —OC(═O)R a , —NR b C(═O)OR d , —NR b C(═O)R a , —C(═O)NR a R b , —NR a R b , —NR c C(═O)NR a R b , —OR a , alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, arylalkyl, and heteroarylalkyl,
or a pharmaceutically acceptable salt thereof.
32. The method of claim 31 , wherein said compound is selected from:
or a pharmaceutically acceptable salt thereof.
33. The method of claim 32 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
34. The method of claim 32 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
35. The method of claim 32 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
36. The method of claim 32 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
37. The method of claim 32 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
38. The method of claim 32 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
39. The method of claim 36 , wherein the compound is administered in combination with a proteasome inhibitor.
40. The method of claim 39 , wherein the proteasome inhibitor is bortezomib.
41. The method of claim 39 , wherein the disorder is selected from acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia and multiple myeloma.
42. The method of claim 41 , wherein the disorder is selected from acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma.
43. The method of claim 42 , wherein the disorder is acute myeloid leukemia.
44. The method of claim 42 , wherein the disorder is chronic myeloid leukemia.
45. The method of claim 42 , wherein the disorder is multiple myeloma.
46. The method of claim 40 , wherein the disorder is selected from acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma.
47. The method of claim 46 , wherein the disorder is acute myeloid leukemia.
48. The method of claim 46 , wherein the disorder is chronic myeloid leukemia.
49. The method of claim 46 , wherein the disorder is multiple myeloma.
50. The method of claim 37 , wherein the compound is administered in combination with a proteasome inhibitor.
51. The method of claim 50 , wherein the proteasome inhibitor is bortezomib.
52. The method of claim 50 , wherein the disorder is selected from acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia and multiple myeloma.
53. The method of claim 52 , wherein the disorder is selected from acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma.
54. The method of claim 53 , wherein the disorder is acute myeloid leukemia.
55. The method of claim 53 , wherein the disorder is chronic myeloid leukemia.
56. The method of claim 53 , wherein the disorder is multiple myeloma.
57. The method of claim 51 , wherein the disorder is selected from acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma.
58. The method of claim 57 , wherein the disorder is acute myeloid leukemia.
59. The method of claim 57 , wherein the disorder is chronic myeloid leukemia.
60. The method of claim 57 , wherein the disorder is multiple myeloma.
61. The method of claim 38 , wherein the compound is administered in combination with a proteasome inhibitor.
62. The method of claim 61 , wherein the proteasome inhibitor is bortezomib.
63. The method of claim 61 , wherein the disorder is selected from acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia and multiple myeloma.
64. The method of claim 63 , wherein the disorder is selected from acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma.
65. The method of claim 64 , wherein the disorder is acute myeloid leukemia.
66. The method of claim 64 , wherein the disorder is chronic myeloid leukemia.
67. The method of claim 64 , wherein the disorder is multiple myeloma.
68. The method of claim 62 , wherein the disorder is selected from acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma.
69. The method of claim 68 , wherein the disorder is acute myeloid leukemia.
70. The method of claim 68 , wherein the disorder is chronic myeloid leukemia.
71. The method of claim 68 , wherein the disorder is multiple myeloma.
72. The method of claim 31 , wherein the compound is administered in combination with a proteasome inhibitor.
73. The method of claim 72 , wherein the proteasome inhibitor is bortezomib.
74. The method of claim 72 , wherein the disorder is selected from acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia and multiple myeloma.
75. The method of claim 74 , wherein the disorder is selected from acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma.
76. The method of claim 75 , wherein the disorder is acute myeloid leukemia.
77. The method of claim 75 , wherein the disorder is chronic myeloid leukemia.
78. The method of claim 75 , wherein the disorder is multiple myeloma.
79. The method of claim 73 , wherein the disorder is selected from acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma.
80. The method of claim 79 , wherein the disorder is acute myeloid leukemia.
81. The method of claim 79 , wherein the disorder is multiple myeloma.
82. The method of claim 81 , wherein the disorder is chronic myeloid leukemia.
83. The method of claim 1 , wherein the compound is administered in combination with a proteasome inhibitor.
84. The method of claim 83 , wherein the proteasome inhibitor is bortezomib.
85. The method of claim 83 , wherein the disease is selected from acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia and multiple myeloma.
86. The method of claim 85 , wherein the disease is selected from acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma.
87. The method of claim 86 , wherein the disease is acute myeloid leukemia.
88. The method of claim 86 , wherein the disease is chronic myeloid leukemia.
89. The method of claim 86 , wherein the disease is multiple myeloma.
90. The method of claim 84 , wherein the disease is selected from acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma.
91. The method of claim 90 , wherein the disease is acute myeloid leukemia.
92. The method of claim 90 , wherein the disease is chronic myeloid leukemia.
93. The method of claim 90 , wherein the disease is multiple myeloma.
94. The method of claim 8 , wherein the compound is administered in combination with a proteasome inhibitor.
95. The method of claim 94 , wherein the proteasome inhibitor is bortezomib.
96. The method of claim 94 , wherein the disease is selected from acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia and multiple myeloma.
97. The method of claim 96 , wherein the disease is selected from acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma.
98. The method of claim 97 , wherein the disease is acute myeloid leukemia.
99. The method of claim 97 , wherein the disease is chronic myeloid leukemia.
100. The method of claim 97 , wherein the disease is multiple myeloma.
101. The method of claim 95 , wherein the disease is selected from acute myeloid leukemia, chronic myeloid leukemia and multiple myeloma.
102. The method of claim 101 , wherein the disease is acute myeloid leukemia.
103. The method of claim 101 , wherein the disease is chronic myeloid leukemia.
104. The method of claim 101 , wherein the disease is multiple myeloma.